Theravance Biopharma
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $26,195 | $15,388 | $18,754 | $16,868 |
Gross Profit | 26,195 | 15,388 | 18,754 | 16,868 |
EBITDA | 74,796 | -12,443 | -7,601 | -8,660 |
EBIT | 73,869 | -13,495 | -8,296 | -9,422 |
Net Income | 54,835 | -13,579 | -15,527 | -12,698 |
Net Change In Cash | 26,195 | 15,388 | 18,754 | 16,868 |
Free Cash Flow | 208,040 | 43,039 | -1,092 | -5,211 |
Cash | 281,927 | 110,614 | 37,797 | 23,378 |
Basic Shares | 50,726 | 49,706 | 49,306 | 49,038 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $64,381 | $57,424 | $51,346 | $55,311 |
Gross Profit | 64,381 | 57,424 | 44,757 | 48,025 |
EBITDA | -38,453 | -42,663 | -79,857 | -249,389 |
EBIT | -42,068 | -46,919 | -86,446 | -256,675 |
Net Income | -56,418 | -55,193 | -92,824 | -199,426 |
Net Change In Cash | 64,381 | 57,424 | 51,346 | 55,311 |
Cost of Revenue | 208,212 | 8,496 | ||
Free Cash Flow | -11,867 | -29,485 | -187,563 | -211,264 |
Cash | 37,797 | 39,545 | 298,172 | 89,959 |
Basic Shares | 48,847 | 55,303 | 73,591 | 69,461 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.08 |
2025-03-31 | -$0.17 |
2024-12-31 | -$0.05 |
